Low‑Grade Non‑Invasive Papillary Urothelial Carcinoma (Ta LG) – Guideline Summary

Initial Treatment

Complete transurethral resection of bladder tumor (TURBT) is the definitive initial therapy; a second resection is unnecessary when the first specimen includes detrusor muscle. (American Society of Clinical Oncology evidence, 2022) 1
A single immediate postoperative intravesical chemotherapy instillation (preferably mitomycin C) should be administered within 24 hours of TURBT. (National Comprehensive Cancer Network guideline, 2020) [1][2]

The immediate instillation reduces the 5‑year recurrence rate from approximately 59 % to 45 % compared with TURBT alone. (Level II evidence, 2022) 1
Progression to muscle‑invasive disease remains negligible (< 2 % at 5 years) for low‑risk Ta disease. (Level II evidence, 2022) 1

Extended intravesical regimens (BCG or additional chemotherapy) are not indicated for low‑risk disease; they are reserved for intermediate‑ and high‑risk NMIBC. (NCCN guideline, 2020) [1][3]

First cystoscopic evaluation should be performed 3–4 months after the initial TURBT. (NCCN guideline, 2020) [2][3]

A follow‑up cystoscopy is recommended at 6–9 months, then annually for up to 5 years. (NCCN guideline, 2020) [2][3]
After 5 years, cystoscopy is performed only for clinical indications (e.g., symptoms). (NCCN guideline, 2020) [2][3]

Cystoscopy is the primary surveillance tool; routine upper‑tract imaging is not required beyond baseline studies in asymptomatic patients. (NCCN guideline, 2020) [2][3]
Urine cytology has limited sensitivity for low‑grade disease and is not routinely recommended. (NCCN guideline, 2020) 2
Urine molecular biomarker assays may improve sensitivity but have lower specificity; their role remains investigational for low‑risk disease. (NCCN guideline, 2020) 2

Recurrent low‑grade papillary lesions detected > 1 year after the prior tumor should be managed with repeat TURBT plus a single immediate intravesical chemotherapy instillation. (ASCO evidence, 2022) 1
Each recurrence warrants restaging and reassessment of risk to determine if treatment strategy should be escalated. (NCCN guideline, 2020) [2][3]

Avoid extended BCG or chemotherapy courses in confirmed low‑risk disease, as they increase toxicity and cost without outcome benefit. (ASCO evidence, 2022; NCCN guideline, 2020) [1][2]
Do not perform routine upper‑tract imaging in asymptomatic low‑risk patients to prevent unnecessary radiation exposure and expense. (NCCN guideline, 2020) 2
Do not extend surveillance intervals beyond the guideline‑recommended schedule during the first 5 years, when the majority of recurrences occur. (NCCN guideline, 2020) [2][3]
Ensure the initial TURBT specimen contains detrusor muscle to confirm accurate staging and avoid understaging. (ASCO evidence, 2022) 1